Template:Published case reports of bicalutamide-associated lung toxicity

From WikiProjectMed
Jump to navigation Jump to search
Published case reports of bicalutamide-associated lung toxicity
# Age Sex Dosage Onset Type of injury Outcome Ref Link(s)
1 69 years Male 200 mg/day 6 months Eosinophilic lung disease Recovered Wong et al. (1998) [1]
2 ~76 years Male 200 mg/day 8 months Interstitial pneumonitis Recovered McCaffrey & Scher (1998) [2][3]
3 ~82 years Male 80 mg/day 4 weeks Interstitial pneumonitis Recovered Shioi et al. (2003) [4]
4 ~72 years Male 80 mg/day 2.5 months Interstitial pneumonitis Recovered, then deatha Shioi et al. (2005) [5]
5 84 years Male ? 8 months Interstitial pneumonitis Recovered Kobayashi et al. (2006) [6]
6 76 years Male ? ? Interstitial pneumonitis ? Gifford & DeLong (2008) [7]
7 85 years Male ? 4 months Interstitial pneumonitis Death Kawahara et al. (2009) [8]
8 78 years Male 80 mg/day 8 months Interstitial pneumonitis Recovered Masago et al. (2011) [9]
9 77 years Male ? 7 months Interstitial pneumonitis Death Song et al. (2014) [10][11]
10 77 years Male >50 mg/day ~12 months Interstitial pneumonitis Death Molina Mancero et al. (2016) [12]
11 79 years Male ? 1 month Interstitial pneumonitis Death Polatoglu et al. (2017) [13]
12 66 years Male ? ? Interstitial pneumonitis Recovered Kim et al. (2018) [14]
13 66 years Male ? ? Interstitial pneumonitis Recovered Derichs et al. (2018) [15]
14 86 years Male 150 mg/day 6 years Eosinophilic pneumonitis Recovered Umeojiako & James (2019) [16]
15 75 years Male ? 2 weeks Interstitial pneumonitis Death Maeda et al. (2019) [8]
16 79 years Male ? 1.5 months Interstitial pneumonitis Recovered Saito (2020) [17]
17 66 years Male 50 mg/day 6 months Interstitial pneumonitis Recovered Smith & Antonarakis (2020) [18]
Footnotes: a = Died of pneumothorax followed by spontaneous rupture of bulla induced by previous interstitial pneumonitis 14 months after discontinuation of bicalutamide and recovery from interstitial pneumonitis. Notes: Twelve additional cases of bicalutamide-associated interstitial pneumonitis, three of which resulted in death, were observed in an 87,000-patient cohort from MedWatch (U.S.Tooltip United States FDATooltip Food and Drug Administration passive adverse-event reporting database) between 1998 and 2000 (0.01% incidence).[19][20][21] The median age of the patients was 73.5 years (range 59 to 91 years), and median duration of bicalutamide exposure was 7.5 weeks (range 1 to 312 weeks).[19] Cases of interstitial pneumonitis have also been reported in association with flutamide, nilutamide, and gonadotropin-releasing hormone (GnRH) agonists.[8][19]